2 years ago

Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to prot

Human cancer cell lines H23 (lung adenocarcinoma) and DLD-one (colon adenocarcinoma) Carfilzomib and oprozomib read more...



2 years ago

Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to prot

Carfilzomib is a novel class of peptidyl epoxyketone proteasome inhibitor and has shown promising

2 years ago

Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to prot

Carfilzomib is an epoxyketone-based Carfilzomib proteasome inhibitor and has proven promising preclinical and scientific exercise in a number read more...



2 years ago

Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to prot

HNSCC is the seventh top Carfilzomib trigger of most cancers fatalities globally.forty eight Current remedy for HNSCC read more...